Zheng, L., Wang, H., Zhou, J., Shi, G., Ma, J., Jiang, Y., Dong, Z., Li, J., He, Y.-Q., Wu, D., Sun, J., Xu, C., Li, Z., Wang, J.

Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin

4 de July de 2024 by Zheng, L., Wang, H., Zhou, J., Shi, G., Ma, J., Jiang, Y., Dong, Z., Li, J., He, Y.-Q., Wu, D., Sun, J., Xu, C., Li, Z., Wang, J.

Background
Chimeric antigen receptor natural killer (CAR-NK) therapy holds great promise for treating hematologic tumors, but its efficacy in solid tumors is limited owing to the lack of suitable targets and poor infiltration of engineered NK cells. H…